Get the Stockscreener App
2.26
8.13%
-0.20
Clearmind Medicine Inc stock is traded at $2.26, with a volume of 104.28K.
It is down -8.13% in the last 24 hours and down -73.54% over the past month.
Clearmind Medicine Inc is a clinical-stage pharmaceutical company engaged in Phase I/IIa clinical trials of novel psychedelic medicines. The Company focuses on developing treatments for mental health disorders, including alcohol use disorder (AUD), binge drinking, and eating disorders. Its activities are centered on the research and development of 5-methoxy-2-aminoindane (MEAI). It operates through a single research and development segment, which is conducted in Israel.
See More
Previous Close:
$2.46
Open:
$2.42
24h Volume:
104.28K
Relative Volume:
0.19
Market Cap:
$2.30M
Revenue:
-
Net Income/Loss:
$-6.64M
P/E Ratio:
-0.1251
EPS:
-18.0702
Net Cash Flow:
$-5.60M
1W Performance:
-56.54%
1M Performance:
-73.54%
6M Performance:
-96.91%
1Y Performance:
-99.44%
1-Day Range:
$2.10
$2.42
1-Week Range:
$2.10
$6.031
52-Week Range:
$2.10
$524.00
Clearmind Medicine Inc Stock (CMND) Company Profile
Compare CMND vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CMND
Clearmind Medicine Inc
|
2.26 | 2.51M | 0 | -6.64M | -5.60M | -18.07 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Clearmind Medicine Inc Stock (CMND) Latest News
Is Clearmind Medicine (NASDAQ:CMND) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
Clearmind Medicine to implement 1-for-10 reverse share split - MSN
Clearmind Medicine stock tumbles on reverse share split plan By Investing.com - Investing.com Nigeria
Dow Falls Over 100 Points; Home Depot Posts Upbeat Earnings - Benzinga
Clearmind Medicine stock tumbles on reverse share split plan - Investing.com
they’re doing it for the hell of it. - Moomoo
Clearmind Medicine to implement 1-for-10 reverse stock split - Investing.com
Clearmind Medicine Inc. Announces 1-for-10 Reverse Share Split to Regain Nasdaq Compliance - Quiver Quantitative
Clearmind Medicine announces 1-for-10 reverse share split - marketscreener.com
Clearmind Medicine to implement 1-for-10 reverse stock split By Investing.com - Investing.com Australia
Clearmind Medicine Announces 1-for-10 Reverse Share Split - The Manila Times
Clearmind Medicine Announces 1-For-10 Reverse Share Split - TradingView
CMND Stock Price, Quote & Chart | CLEARMIND MEDICINE INC (NASDAQ:CMND) - ChartMill
$Clearmind Medicine (CMND.US)$[Lol][Lol][Lol] - Moomoo
Clearmind signs research deal to study obesity drug combination By Investing.com - Investing.com Australia
Clearmind signs research deal to study obesity drug combination - Investing.com UK
Tirzepatide Combination Study Expands Clearmind’s Obesity Therapy Strategy (CMND) - Yahoo Finance
Clearmind Medicine Signs Agreement to Examine MEAI in Combination and Sequencing with Tirzepatide Against Blockbuster GLP-1 Medications - The Manila Times
Clearmind Medicine Inc. And Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Sign Agreement To Examine MEAI In Combination And Sequencing With Tirzepatide - marketscreener.com
Clearmind Medicine CEO Dr. Adi Zuloff-Shani Participates in Psychedelic Medicine Coalition Federal Policy Summit - Quiver Quantitative
Clearmind Medicine CEO Dr. Adi Zuloff-Shani named Delegate to Federal Policy Summit on Psychedelic Medicine in Washington, D.C. - The Manila Times
Number of shareholders of Clearmind Medicine Inc. – NASDAQ:CMND - TradingView
TradingKey - TradingKey
Clearmind doses two more patients in alcohol disorder trial - Investing.com UK
Clearmind Medicine Treats 20 Participants in CMND-100 Alcohol Use Disorder Trial - geneonline.com
20 patients treated in Clearmind (Nasdaq: CMND) Phase I/IIa AUD study - Stock Titan
Clearmind doses two more patients in alcohol disorder trial By Investing.com - Investing.com Australia
Clearmind Medicine Reaches Important Clinical Milestone: 20 Participants Now Treated in Ongoing Phase I/IIa Trial of CMND-100 for Alcohol Use Disorder - The Manila Times
Clearmind Medicine Reaches Important Clinical Milestone: 20 Participants Now Treated in Ongoing ... - Caledonian Record
Novel non-hallucinogenic alcohol use disorder drug reaches 20 patients - Stock Titan
Clearmind Medicine Inc. Advances Phase I/IIa Trial of CMND-100 for Alcohol Use Disorder, Dosing Milestone Reached - Quiver Quantitative
Clearmind Medicine announces "Inside MEAI" webinar featuring new insights from CMND-100 psychedelic clinical trial - marketscreener.com
Webinar to unpack new data on non-hallucinogenic alcohol addiction drug candidate - Stock Titan
Clearmind Medicine Announces “Inside MEAI” Webinar Featuring New Insights from CMND-100 Psychedelic Clinical Trial - marketscreener.com
Clearmind shares surge as CMND-100 achieves primary endpoint in clinical trial - MSN
[EFFECT] Clearmind Medicine Inc. SEC Filing - Stock Titan
CMND: Clearmind Medicine Inc.Interactive Chart - Zacks Investment Research
Clearmind Medicine Stock Quote, Share Price, News and Analysis - Longbridge
Clearmind files European patent for PTSD treatment compounds By Investing.com - Investing.com South Africa
Clearmind files European patent for PTSD treatment compounds - Investing.com UK
Clearmind Medicine Inc. Files European Patent Application for Innovative Psychedelic Compounds Targeting PTSD Treatment - Moomoo
Clearmind (Nasdaq: CMND) files European patent for PTSD psychedelics - Stock Titan
Clearmind Medicine Announces Filing Of European Patent Application For Novel Psychedelic Compounds For The Treatment Of Ptsd - TradingView
Clearmind seeks European patent for psychedelic PTSD compounds - Stock Titan
Clearmind Medicine Announces Filing of European Patent Application for Novel Psychedelic ... - Caledonian Record
Clearmind Medicine Announces Filing of European Patent Application for Novel Psychedelic Compounds for the Treatment of PTSD - marketscreener.com
Clearmind Medicine Inc Stock (CMND) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.98%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):